For the management of relapsed and refractory myeloma patients there are multiple combinations but at the end of the day we have to consider that, until now, the three pillars of treatment for patients with multiple myeloma have been proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies. According to the current guidelines, between the first two or three, maybe until the fourth line of therapy, the majority of our patients with myeloma are going to be exposed to these three main drug classes – proteasome inhibitors, IMiDs and anti-CD38 monoclonal antibodies – and when this happens the main problem is that there is not any standard of care for the rescue of these patients with multiple myeloma that we can call triple-drug class exposed.